purpose the aim of this study was to estimate both the direct and indirect annual cost of managing dry eye disease ded in the united states from a societal and a payers perspectivemethods a decision analytic model was developed to estimate the annual cost for managing a cohort of patients with dry eye with differing severity of symptoms and treatmentthe direct costs included ocular lubricants cyclosporine punctal plugs physician visits and nutritional supplementsthe indirect costs were measured as the productivity loss because of absenteeism and presenteeismthe model was populated with data that were obtained from surveys that were completed by dry eye sufferers who were recruited from online databasessensitivity analyses were employed to evaluate the impact of changes in parameters on the estimation of costsall costs were converted to 2008 us dollarsresults survey data were collected from 2171 respondents with dedour analysis indicated that the average annual cost of managing a patient with dry eye at 783 variation 757809 from the payers perspectivewhen adjusted to the prevalence of ded nationwide the overall burden of ded for the us healthcare system would be 384 billionfrom a societal perspective the average cost of managing ded was estimated to be 11302 per patient and 554 billion to the us society overallconclusions ded poses a substantial economic burden on the payer and on the societythese findings may provide valuable information for health plans or employers regarding budget estimation